Matches in SemOpenAlex for { <https://semopenalex.org/work/W1796737646> ?p ?o ?g. }
- W1796737646 endingPage "73" @default.
- W1796737646 startingPage "73" @default.
- W1796737646 abstract "Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials Donald P Tashkin1, Dennis E Doherty2, Edward Kerwin3, Carlos E Matiz-Bueno4, Barbara Knorr5, Tulin Shekar5, Davis Gates5, Heribert Staudinger51David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, KY, 3Clinical Research Institute of Southern Oregon, Medford, OR, USA; 4Fundación Salud Bosque, Bogota, Colombia, 5Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USABackground: The clinical efficacy and safety of a mometasone furoate/formoterol fumarate (MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was investigated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).Methods: Two 52-week, multicenter, double-blind, placebo-controlled trials with identical study designs were conducted in current or ex-smokers (aged ≥40 years), and pooled study results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily treatment with MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg, F 10 µg, or placebo. After the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean changes in forced expiratory volume in one second (FEV1), area under the curve from 0 to 12 hours postdose (AUC0–12 h), and morning predose/trough FEV1 from baseline to the week 13 endpoint. Key secondary efficacy variables were St George’s Respiratory Questionnaire scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week 26 endpoint.Results: In the 26-week treatment period, significantly greater increases in FEV1 AUC0–12 h occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints (P ≤ 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400. Also, significantly greater increases in morning predose/trough FEV1 occurred with MF/F 400/10 versus F 10 and placebo at the week 13 endpoint (P < 0.05). The increase was four-fold greater with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically important differences from baseline (>4 units) in St George’s Respiratory Questionnaire scores at week 26. Symptom-free nights increased by ≥14% in the MF/F 400/10, MF 400, and F 10 groups (P ≤ 0.033 versus placebo). The incidence of exacerbations was lower in the MF/F groups (≤33.3%) than it was in the MF, formoterol, and placebo groups (≥33.8%) over the 26-week treatment period. The incidence of adverse events was similar in the active-treated and placebo-treated subjects across 26 weeks of treatment. Over the 1-year study period, there were no notable differences in the incidence or types of adverse events between the MF/F 400/10 and MF/F 200/10 groups compared with the MF or formoterol groups. Differences in rates of individual treatment-emergent adverse events were" @default.
- W1796737646 created "2016-06-24" @default.
- W1796737646 creator A5020858694 @default.
- W1796737646 creator A5025257736 @default.
- W1796737646 creator A5029859348 @default.
- W1796737646 creator A5048002347 @default.
- W1796737646 creator A5062711392 @default.
- W1796737646 creator A5069610412 @default.
- W1796737646 creator A5084674991 @default.
- W1796737646 creator A5091200779 @default.
- W1796737646 date "2012-02-01" @default.
- W1796737646 modified "2023-09-30" @default.
- W1796737646 title "Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials" @default.
- W1796737646 cites W1549228288 @default.
- W1796737646 cites W1554562511 @default.
- W1796737646 cites W1920721512 @default.
- W1796737646 cites W1964918370 @default.
- W1796737646 cites W1989738601 @default.
- W1796737646 cites W1990655430 @default.
- W1796737646 cites W2002726093 @default.
- W1796737646 cites W2004106499 @default.
- W1796737646 cites W2006193143 @default.
- W1796737646 cites W2019643126 @default.
- W1796737646 cites W2031245994 @default.
- W1796737646 cites W2040683479 @default.
- W1796737646 cites W2045640813 @default.
- W1796737646 cites W2052977441 @default.
- W1796737646 cites W2057984874 @default.
- W1796737646 cites W2058580481 @default.
- W1796737646 cites W2083436606 @default.
- W1796737646 cites W2084702877 @default.
- W1796737646 cites W2088022718 @default.
- W1796737646 cites W2088889277 @default.
- W1796737646 cites W2091330727 @default.
- W1796737646 cites W2105281080 @default.
- W1796737646 cites W2108337616 @default.
- W1796737646 cites W2108808404 @default.
- W1796737646 cites W2112433656 @default.
- W1796737646 cites W2113442593 @default.
- W1796737646 cites W2120629366 @default.
- W1796737646 cites W2120698097 @default.
- W1796737646 cites W2123265078 @default.
- W1796737646 cites W2123820104 @default.
- W1796737646 cites W2125078269 @default.
- W1796737646 cites W2127019399 @default.
- W1796737646 cites W2127370507 @default.
- W1796737646 cites W2127951128 @default.
- W1796737646 cites W2132084781 @default.
- W1796737646 cites W2133119676 @default.
- W1796737646 cites W2133928926 @default.
- W1796737646 cites W2138944121 @default.
- W1796737646 cites W2139868234 @default.
- W1796737646 cites W2141034778 @default.
- W1796737646 cites W2142724633 @default.
- W1796737646 cites W2145152803 @default.
- W1796737646 cites W2146877487 @default.
- W1796737646 cites W2149199480 @default.
- W1796737646 cites W2149279454 @default.
- W1796737646 cites W2158553376 @default.
- W1796737646 cites W2165087980 @default.
- W1796737646 cites W2166432084 @default.
- W1796737646 cites W2167089458 @default.
- W1796737646 cites W2171853330 @default.
- W1796737646 cites W2172097057 @default.
- W1796737646 cites W2322866941 @default.
- W1796737646 cites W2417515221 @default.
- W1796737646 cites W44494638 @default.
- W1796737646 cites W2736324050 @default.
- W1796737646 cites W2916511598 @default.
- W1796737646 doi "https://doi.org/10.2147/copd.s29444" @default.
- W1796737646 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3276258" @default.
- W1796737646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22334770" @default.
- W1796737646 hasPublicationYear "2012" @default.
- W1796737646 type Work @default.
- W1796737646 sameAs 1796737646 @default.
- W1796737646 citedByCount "22" @default.
- W1796737646 countsByYear W17967376462013 @default.
- W1796737646 countsByYear W17967376462014 @default.
- W1796737646 countsByYear W17967376462015 @default.
- W1796737646 countsByYear W17967376462016 @default.
- W1796737646 countsByYear W17967376462017 @default.
- W1796737646 countsByYear W17967376462018 @default.
- W1796737646 countsByYear W17967376462020 @default.
- W1796737646 countsByYear W17967376462021 @default.
- W1796737646 countsByYear W17967376462022 @default.
- W1796737646 countsByYear W17967376462023 @default.
- W1796737646 crossrefType "journal-article" @default.
- W1796737646 hasAuthorship W1796737646A5020858694 @default.
- W1796737646 hasAuthorship W1796737646A5025257736 @default.
- W1796737646 hasAuthorship W1796737646A5029859348 @default.
- W1796737646 hasAuthorship W1796737646A5048002347 @default.
- W1796737646 hasAuthorship W1796737646A5062711392 @default.
- W1796737646 hasAuthorship W1796737646A5069610412 @default.
- W1796737646 hasAuthorship W1796737646A5084674991 @default.
- W1796737646 hasAuthorship W1796737646A5091200779 @default.
- W1796737646 hasBestOaLocation W17967376461 @default.
- W1796737646 hasConcept C126322002 @default.
- W1796737646 hasConcept C142724271 @default.